Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
38,450
+250 (0.65%)
Apr 28, 2026, 3:30 PM KST
-28.93%
Market Cap 1.13T
Revenue (ttm) 83.13B
Net Income (ttm) -47.39B
Shares Out 29.28M
EPS (ttm) -2,825.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 154,917
Average Volume 161,652
Open 38,200
Previous Close 38,200
Day's Range 37,400 - 39,250
52-Week Range 31,800 - 60,700
Beta 1.25
RSI 57.42
Earnings Date May 14, 2026

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Sector Technology
Founded 2013
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2025, Lunit's revenue was 83.13 billion, an increase of 53.43% compared to the previous year's 54.18 billion. Losses were -47.39 billion, -42.69% less than in 2024.

Financial Statements

News

There is no news available yet.